Compare TransMedics Group Inc (TMDX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wells Fargo & Co — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Wells Fargo & Co trades at $90 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 86.9× TransMedics Group Inc's market cap, and Wells Fargo & Co pays a 2.27% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WFC | |
|---|---|---|
Market Cap | $3.06B | $265.99B |
Sector | Technology | Financials |
52-Week High | $150.42 | $96.40 |
52-Week Low | $61.99 | $73.42 |
Enterprise Value | $3.46B | — |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, amid mixed earnings performance but strong profitability trends. The stock shows a bullish technical signal with support near $87 and resistance at $89, while fundamentals reveal a P/E of 12.78 and net income margin of 25.97% for 2025. Recent news highlights CEO Charlie Scharf's focus on dealmaking and a push to expand wealth management, with institutional buying activity noted in August 2026 filings.
Outlook remains cautiously optimistic with a consensus price target of $97.64, implying 11% upside, supported by improved return on tangible common equity and dividend payments. Risks include volatile cash flows, regulatory scrutiny, and interest rate sensitivity. Analyst consensus is balanced with 45% buy ratings, but recent earnings misses warrant monitoring execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
